KinderPharm Raises $1 Million to Further Advance Pediatric Drug Development

KinderPharm, a full-service contract research organization (CRO) dedicated exclusively to pediatric drug development, has raised $1 million from a Series A, comprised of individuals, companies and angel investors. The $1 million investment will be used to further advance the clinical development of new medicines for children.
EXTON, Pa. - Aug. 12, 2015 - PRLog -- Bringing Better Medicines to Children

The recently changed pharmaceutical industry’s perspective – as a result of legislative initiatives in both the US and Europe, and the increasing pressure from patients’ groups – created great opportunities for pediatric drug development. Our “Pediatric Center of Excellence” model is a unique resource of pediatricians, pharmacometricians, regulatory, drug safety and formulation scientists that develop pediatric drugs through all stages of development. Our seasoned teams bring expertise and insight to pharmaceutical companies of all sizes to help effectively navigate the complex pediatric regulatory environments in the US and Europe. With our partners we design, manage and conduct all aspects of pediatric product development including:

     Waivers and deferrals

     Age appropriate pediatric formulations

     Juvenile toxicology studies

     Protocol design

     Dose extrapolation

     PK/PD modeling and simulation

     Population PK/sparse sampling strategies

     PDP, PSP and PIP applications

     Pediatric clinical trials

     Regulatory strategy and submissions

For further information, please contact:

Martin Graham, PhD, Chief Executive Officer,  (610) 458-1052

Janet Welsko, Chief Operating Officer, (610) 458-1052

Lynda Graham, MBA, Chief Financial Officer, (610) 458-1052

For media inquiries, please contact:

Kristin Liezenga, Business Development Executive, (610) 458-1502

Lynda Graham

Like PRLog?
Click to Share